Mark Robson
马克·罗布森
MD
Chief, Breast Medicine Service乳腺医学服务主任
👥Biography 个人简介
Leading expert in BRCA-associated breast cancers at MSKCC, internationally recognized for pivotal trials of PARP inhibitors in BRCA mutation carriers. His research bridging hereditary cancer genetics and targeted therapy has transformed treatment for patients with inherited breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibitor Clinical Trials
Led the OlympiAD trial demonstrating olaparib superiority over chemotherapy in BRCA-mutated metastatic breast cancer, establishing PARP inhibitors as standard of care.
BRCA Cancer Management
Defined evidence-based screening, prevention, and treatment strategies for BRCA1/2 mutation carriers, incorporated into international breast cancer treatment guidelines.
Representative Works 代表性著作
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation (OlympiAD)
New England Journal of Medicine (2017)
Practice-changing trial establishing olaparib as first approved PARP inhibitor for BRCA-mutated metastatic breast cancer.
BRCA1 and BRCA2 hereditary breast and ovarian cancer
New England Journal of Medicine (2016)
Comprehensive clinical review covering risk assessment, surveillance, prevention, and treatment for BRCA mutation carriers.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Mary-Claire King
University of Washington
Kenneth Offit
Memorial Sloan Kettering Cancer Center
Judy Garber
Dana-Farber Cancer Institute
Barbara Biesecker
RTI International / NHGRI
关注 马克·罗布森 的研究动态
Follow Mark Robson's research updates
留下邮箱，当我们发布与 Mark Robson（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment